LUND, SE / ACCESSWIRE / November 30, 2023 / Cantargia (STO:CANTA)
The number of shares and votes in Cantargia AB (publ) has changed due to the recently completed directed new share issue (for further information, see the company's press release on 30 October 2023). Through the directed new share issue, the number of shares and votes in Cantargia increased by 16,698,789. Today, on the last trading day of the month, there are in total 183,686,684 shares and votes in Cantargia.
For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com
This information is information that Cantargia is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-11-30 13:00 CET.
About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. The main program, the antibody nadunolimab (CAN04), is being studied clinically primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive interim data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.
Attachments
New number of shares and votes in Cantargia
SOURCE: Cantargia
View source version on accesswire.com:https://www.accesswire.com/811711/new-number-of-shares-and-votes-in-cantargia
